对以维拉帕米(异搏定,下简VP)静注3mg 和口服80mg 后的晚期慢性肾衰竭患者和健康受试者进行了药动学研究。用HPLC 测定血药水平及活性代谢物去甲维拉帕米(去甲VP)。静注VP 后,血药水平下降先快后慢。两组血药水平相同。血药曲线呈开放二室模型。两组有关药动学参数亦相同,血浆去甲VP 浓度 Pharmacokinetic studies were conducted in patients with advanced chronic renal failure and in healthy subjects who received intravenous 3 mg and oral 80 mg of verapamil (Verapamil, Viennese VP). Plasma levels and the active metabolite of norvirabapir (nor-VP) were determined by HPLC. After the intravenous injection of VP, blood drug levels decreased first and then slow. The two groups of blood levels the same. Blood curve is open two-compartment model. Pharmacokinetic parameters of the two groups are also the same, the plasma concentration of norepinephrine